Equine sarcoid tumour treated by autogenous tumour vaccine.

This research is about treating equine sarcoid tumours using a patient-derived vaccine, showcasing its effectiveness in producing long disease-free intervals and its potential to trigger remission in recurrent cases.

Overview of the Study

• The research focuses on treating sarcoid tumours in horses using autogenous vaccines, which are derived from the patients’ own tumour tissue. Conducted from 1991 to 1997, the study treats 21 horses suffering from this type of tumour.
• During the procedures, the base of the tumour was intentionally left in the skin, forming an internal control group for the study, while the extirpated tumour tissue was used to make autovaccines through a process called polymerization.
• A group of 12 horses had primary tumours and another group of 9 horses had recurring tumours prior to the bio-immunotherapy.

Study Findings and Conclusions

• Out of the 12 horses initially presenting with a primary tumour, only one developed a recurrence post-vaccination. In the group with recurring tumours, four out of nine had a single recurrence.
• Four out of these five horses with recurrence were treated again, leading them to remission, demonstrating the beneficial effect of the autogenous vaccine treatment even in repeated use.
• Key findings point toward autovaccine treatment resulting in longer disease-free intervals for both primary and recurrent sarcoids, when compared to conventional surgery alone. Statistical significance was confirmed with p-values of 0.0005 and 0.0156 respectively.
• Furthermore, the researchers hint at “mitochondrial events” influencing the healing process, implying that certain biochemical events at the cellular level, attributed to the organelle responsible for energy production in cells, may be involved.

Implication of the Study

• This research supports the use of autogenous vaccines as a promising treatment for equine sarcoid tumours. The produced vaccines from the horses’ own tumours appear to result in longer disease-free periods and fewer recurrences.
• However, a deeper understanding of the implied “mitochondrial events” and their role in the healing process would require additional studies to fully comprehend the potential mechanisms behind the success of this treatment method.